Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.

Journal of neuro-oncology - 1 May 2021

Dono Antonio, Mitra Sonali, Shah Mauli, Takayasu Takeshi, Zhu Jay-Jiguang, Tandon Nitin, Patel Chirag B, Esquenazi Yoshua, Ballester Leomar Y

Abstract excerpt

INTRODUCTION: Optimal treatment for recurrent glioblastoma isocitrate dehydrogenase 1 and 2 wild-type (rGBM IDH-WT) is not standardized, resulting in multiple therapeutic approaches. A phase III clinical trial showed that tumor treating fields (TTFields) monotherapy provided comparable survival benefits to physician's chemotherapy choice in rGBM. However, patients did not equally benefit from TTFields,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Chronic Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Mutation

Share to PTEN Phosphohydrolase

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 33881725
DOI: 10.1007/s11060-021-03755-1
PMCID: PMC8363068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.PMID 33881725Read ↗

Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.Semantic proximity Read ↗

Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.Semantic proximity Read ↗

Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical ModelsSemantic proximity Read ↗

Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical ModelsSemantic proximity Read ↗

Survival Impact of Isocitrate Dehydrogenase (IDH)-Wildtype Histological Versus Molecular Glioblastoma: A Propensity Score-Matched AnalysisSemantic proximity Read ↗

Experience about Chemoradiation treatment with or without Concurrent Tumor-Treating Fields (TTFields) in Newly Diagnosed Glioblastoma (GBM) Patients in ChinaSemantic proximity Read ↗

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Semantic proximity Read ↗

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastomaSemantic proximity Read ↗

Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatmentSemantic proximity Read ↗

Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators.Semantic proximity Read ↗

Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.Semantic proximity Read ↗

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.